TrialPath
Pancreatic cancer · Phoenix

Pancreatic cancer clinical trials in Phoenix

20 recruiting pancreatic cancer studies within range of Phoenix. Click any trial for full eligibility criteria and contact info.

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

NCT06026410 · Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Recruiting

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

PhasePhase 1
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 37 more
SponsorKura Oncology, Inc.
▾Tap for details
Apply

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

NCT06131840 · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms
Recruiting

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Participants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body. This study has 5 different study parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers. Part D and E of the study, together with information from Parts A and B, will find out how much PF-08046050 should be given in combination with other anti-cancer agents. Part E will use the information from Parts A, B, and D to see if PF-08046050 is safe in combination with other anti-cancer agents and if it works to treat a certain solid tumor.

PhasePhase 1
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 47 more
SponsorSeagen, a wholly owned subsidiary of Pfizer
▾Tap for details
Apply

PROMs After Pancreatectomy

NCT07173257 · Pancreas Neoplasms, Pancreatitis, Pancreatic Cyst
Recruiting

The standard of care for a patient with resectable pancreatic is to perform pancreatic resection which, even in the modern era is associated with significant complications and impact on quality of life, often in the setting of poor survival even in the best scenario. Currently, there is a lack of data on patient quality of life after such procedures, how quality of life changes throughout the course of care, and whether patients who undergo these procedures are satisfied with their decision. This research is aimed to understand the impact of pancreatic surgery on patients' quality of life, how that impact changes over time, and patient satisfaction (or regret) with their decisions. This work will help improve the pre-operative conversation to help patients decide whether undergoing a pancreatic resection aligns with their post-operative goals of care.

Phase—
TypeObservational
Age18 Years
WherePhoenix, Arizona, United States + 1 more
SponsorUniversity of Arizona
▾Tap for details

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

Recruiting

The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.

PhasePhase 3
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 5 more
SponsorRevolution Medicines, Inc.
▾Tap for details
Apply

Pancreatic Cancer Early Detection Consortium

NCT04970056 · Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma
Recruiting

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Phase—
TypeObservational
Age18 Years – 90 Years
WherePhoenix, Arizona, United States + 61 more
SponsorArbor Research Collaborative for Health
▾Tap for details
Apply

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437 · Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Recruiting

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.

PhasePhase 2 / Phase 3
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 229 more
SponsorPfizer
▾Tap for details
Apply

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

NCT06998940 · Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Recruiting

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating patients with KRAS wild type (WT) pancreatic ductal adenocarcinoma that cannot be removed by sugery (unresectable) or that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as nanoliposomal irinotecan, leucovorin, 5-FU, irinotecan, nab-paclitaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding panitumumab to standard chemotherapy may be effective in treating patients with unresectable, locally advanced, or metastatic KRAS WT pancreatic ductal adenocarcinoma.

PhasePhase 3
TypeInterventional
Age18 Years
WhereAnchorage, Alaska, United States + 273 more
SponsorSWOG Cancer Research Network
▾Tap for details

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07450859 · Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting

This is a Phase 2 study for nuzefatide pevedotin (BT5528) in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment or two prior lines of treatment if treated with KRAS inhibitor. The drug, nuzefatide pevedotin (nuzefatide), is designed to find a specific protein called EphA2. The main aims of the study are to see how well the drug works against the tumor (efficacy), what side effects it may have (safety), and how the body processes it (pharmacokinetics). All participants in this study will receive nuzefatide, and both they and their doctors will know what is being administered (single-arm, open-label). The trial will take place at several different medical centers.

PhasePhase 2
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 7 more
SponsorBicycleTx Limited
▾Tap for details
Apply

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

NCT05245500 · Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors
Recruiting

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

PhasePhase 1
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 24 more
SponsorBristol-Myers Squibb
▾Tap for details
Apply

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT07277413 · Bladder Cancer, Mesothelioma, Pleural Mesothelioma
Recruiting

\[LM2.1\]This multicenter study will evaluate the safety, efficacy, and pharmacokinetics (PK) of IDE892, alone or in combination with IDE397 or RO7673396, in participants with advanced solid tumors harboring methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

PhasePhase 1
TypeInterventional
Age18 Years
WhereGoodyear, Arizona, United States + 25 more
SponsorIDEAYA Biosciences
▾Tap for details
Apply

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

NCT07165132 · GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease
Recruiting

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

PhasePhase 1
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 14 more
SponsorRayzeBio, Inc.
▾Tap for details
Apply

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Recruiting

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

PhasePhase 3
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 24 more
SponsorRevolution Medicines, Inc.
▾Tap for details
Apply

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Recruiting

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Phase—
TypeObservational
Age40 Years – 75 Years
WhereAnchorage, Alaska, United States + 750 more
SponsorAlliance for Clinical Trials in Oncology
▾Tap for details
Apply

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

NCT05040360 · Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8
Recruiting

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

PhasePhase 2
TypeInterventional
Age18 Years
WhereAnchorage, Alaska, United States + 447 more
SponsorSWOG Cancer Research Network
▾Tap for details

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232 · Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Recruiting

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

PhasePhase 3
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 85 more
SponsorRevolution Medicines, Inc.
▾Tap for details
Apply

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

PhasePhase 3
TypeInterventional
Age18 Years
WhereHuntsville, Alabama, United States + 75 more
SponsorImmuneering Corporation
▾Tap for details
Apply

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

NCT04239573 · Pancreatic Neoplasm
Recruiting

The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers. The study doctors want to compare more frequent monitoring versus less frequent monitoring as well as identify biomarkers which may improve risk detection of transformation to pancreatic cancer. The study doctors want to learn which monitoring method and which biomarkers lead to better outcomes for patients.

Phase—
TypeObservational
Age50 Years – 75 Years
WhereBirmingham, Alabama, United States + 428 more
SponsorECOG-ACRIN Cancer Research Group
▾Tap for details

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT06958328 · Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Recruiting

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care options include additional chemotherapy, observation, or standard lower-dose radiation therapy. These treatments may delay tumor growth but have not been shown to improve survival. Radiation therapy uses high energy X-rays to kill cancer cells and shrink tumors. Dose-escalated radiation therapy involves the precise delivery of higher doses to the tumor, often over a shorter period of time. This trial assesses whether using dose-escalated radiation therapy can prolong survival.

PhasePhase 3
TypeInterventional
Age18 Years
WhereGilbert, Arizona, United States + 332 more
SponsorNRG Oncology
▾Tap for details

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06179160 · Solid Tumors
Recruiting

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

PhasePhase 1
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 33 more
SponsorIncyte Corporation
▾Tap for details
Apply

Pancreatic Cancer Detection Consortium

NCT06388967 · Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Adenocarcinoma
Recruiting

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

Phase—
TypeObservational
Age18 Years
WherePhoenix, Arizona, United States + 12 more
SponsorCity of Hope Medical Center
▾Tap for details
Apply